The federal government is suing some major pharmacy benefit managers for their role in driving up the price of insulin for diabetic patients. The companies targeted in the lawsuit are Caremark, Express Scripts, and OptumRx, which collectively process approximately 80% of prescriptions in the United States.

The Federal Trade Commission alleges that these pharmacy benefit managers have engaged in anticompetitive practices that have led to inflated prices for insulin. PBMs are responsible for managing prescription drug coverage for various clients, negotiating rebates with drug manufacturers, and setting up formularies.

According to the FTC, the current system favors insulins with high list prices, resulting in higher out-of-pocket costs for patients. While PBMs argue that they play a vital role in controlling drug costs, the government claims that their practices have prioritized profits over patient affordability.

Despite the allegations, some of the PBMs named in the lawsuit defend their practices, stating that they negotiate discounts for clients and help make insulin more affordable. Express Scripts, for example, accuses the FTC of focusing on politics rather than consumer protection.

The FTC’s lawsuit underscores the ongoing debate surrounding the role of PBMs in the healthcare system and their impact on drug pricing. As the legal battle unfolds, the implications for patients, insurers, and drug manufacturers remain uncertain.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.